Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

for
Neoplasm Malignant
Location: New Brunswick NJ, Montreal, Baltimore MD, Ottawa,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07209111

Phase 2, Recruiting

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

for
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Plexium, Inc.

Sex: All

Age: 18+

Code: NCT07284186

Phase 1, Recruiting

Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

for
Skin Diseases, Keloid, Scar, Fibrosis, Hypertrophic Skin
Location: Mather CA
Sponsor: VA Northern California Health Care System

Sex: All

Age: 18+

Code: NCT03433222

Phase 1, Recruiting

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

for
Breast Cancer, Lung Cancer (Diagnosis), Prostate Cancer
Location: Orlando FL
Sponsor: AdventHealth

Sex: All

Age: 18+

Code: NCT07231159

Recruiting

EHR Intervention to Increase HBOC Genetic Testing

for
Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
Location: New York NY
Sponsor: Columbia University

Sex: Female

Age: 21 - 70+

Code: NCT07876349

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Ann Arbor MI
Sponsor: University of Michigan Rogel Cancer Center

Sex: All

Age: 18 - 39

Code: NCT07772596

Recruiting

Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry

for
Breast Cancer
Location: Mobile AL, Palo Alto CA
Sponsor: Lumicell, Inc.

Sex: All

Age: 18+

Code: NCT07616856

Recruiting

Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)

for
Cannabis Use, Cancer
Location: Saint Louis Park MN
Sponsor: HealthPartners Institute

Sex: All

Age: 18+

Code: NCT07227324

Recruiting

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

for
Breast Cancer, Cervical Cancer, Bladder Cancer,
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 65+

Code: NCT07227077

Recruiting

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

for
Advanced Solid Tumors
Location: Cleveland OH, St Louis MO, Rochester MN,
Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Sex: All

Age: 18+

Code: NCT06973564

Phase 1, Phase 2, Recruiting

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Ann Arbor MI
Sponsor: University of Michigan Rogel Cancer Center

Sex: Female

Age: 18+

Code: NCT07158021

Phase 2, Recruiting

A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

for
Advanced Solid Tumors, Malignant Neoplasm
Location: San Antonio TX
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07785609

Phase 2, Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Providence RI, New Haven CT, Miami FL, Charleston SC,
Sponsor: Eikon Therapeutics

Sex: All

Age: 18 - 70+

Code: NCT06253130

Phase 1, Phase 2, Recruiting

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

for
Breast Cancer
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All

Age: 18+

Code: NCT04523857

Phase 2, Recruiting

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

for
Small Cell Lung Cancer Extensive Stage, Brain Metastases,
Location: Dallas TX
Sponsor: University of Texas Southwestern Medical Center

Sex: All

Age: 18+

Code: NCT07139990

Phase 1, Recruiting

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

for
Cancer
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT02090530

Recruiting

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

for
Cardiotoxicity, Pediatric Cancer, Heart Failure
Location: San Diego CA
Sponsor: Hari Narayan

Sex: All

Age: 13 - 39

Code: NCT04262830

Recruiting

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

for
Breast Carcinoma, Lung Carcinoma
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center

Sex: All

Age: 40 - 70+

Code: NCT05978128

Recruiting

Radiation Therapy and Thymus Function in Young Women With Breast Cancer

for
Breast Cancer
Location: Durham NC
Sponsor: Duke University

Sex: Female

Age: 18 - 50

Code: NCT07725172

Recruiting

Registry of Older Patients With Cancer

for
Chronic Myeloproliferative Disorders,
Location: Morehead City NC, New Bern NC, Greenville NC,
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 65+

Code: NCT01137825

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial